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ORIGINAL RESEARCH
Biomarkers of Inflammation and Risk of 
Hospitalization for Heart Failure in Patients 
With Atrial Fibrillation
Alexander P. Benz , MD, MSc; Stefanie Aeschbacher , PhD; Philipp Krisai , MD; Giorgio Moschovitis , MD; 
Steffen Blum , MD, PhD; Pascal Meyre , MD, PhD; Manuel R. Blum , MD, MSc; Nicolas Rodondi , MD, MAS; 
Marcello Di Valentino, MD; Richard Kobza , MD; Maria Luisa De Perna , MD; Leo H. Bonati , MD; 
Jürg H. Beer , MD; Michael Kühne , MD; Stefan Osswald , MD; David Conen , MD, MPH;  
on behalf of the BEAT- AF, Swiss- AF Investigators*
BACKGROUND: Hospitalization for heart failure (HF) is very common in patients with atrial fibrillation (AF). We hypothesized that 
biomarkers of inflammation can identify patients with AF at increased risk of this important complication.
METHODS AND RESULTS: Patients with established AF were prospectively enrolled. Levels of hs- CRP (high- sensitivity C- reactive 
protein) and interleukin- 6 were measured from plasma samples obtained at baseline. We calculated an inflammation score 
ranging from 0 to 4 (1 point for each biomarker between the 50th and 75th percentile, 2 points for each biomarker above 
the 75th percentile). Individual associations of biomarkers and the inflammation score with HF hospitalization were obtained 
from multivariable Cox proportional hazards models. A total of 3784 patients with AF (median age 72 years, 24% prior HF) 
were followed for a median of 4.0 years. The median (interquartile range) plasma levels of hs- CRP and interleukin- 6 were 
1.64 (0.81– 3.69) mg/L and 3.42 (2.14– 5.60) pg/mL, respectively. The overall incidence of HF hospitalization was 3.04 per 
100 person- years and increased from 1.34 to 7.31 per 100 person- years across inflammation score categories. After multi-
variable adjustment, both biomarkers were significantly associated with the risk of HF hospitalization (per increase in 1 SD, 
adjusted hazard ratio [HR], 1.22; 95% CI, 1.11– 1.34 for log- transformed hs- CRP; adjusted HR, 1.48; 95% CI, 1.35– 1.62 for 
log- transformed interleukin- 6). Similar results were obtained for the inflammation score (highest versus lowest score, adjusted 
HR, 2.43; 95% CI, 1.80– 3.30; P value for trend <0.001).
CONCLUSIONS: Biomarkers of inflammation strongly predicted HF hospitalization in a large, contemporary sample of patients 
with AF.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT02105844.
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Atrial fibrillation (AF) and its associated complica-tions are a major burden for healthcare systems around the world.1 The global incidence and 
prevalence of AF are expected to rise further in light of 
an ever- increasing life expectancy.2 Although the risk 
of thromboembolic complications such as ischemic 
stroke can be effectively mitigated by long- term oral 
anticoagulation,3 event rates for other important out-
comes, such as hospitalization for heart failure and 
death, remain high.4 Unlike the risk of stroke, the in-
cidence of heart failure among patients with AF has 
not changed over at least 2 decades.5 In fact, heart 
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failure accounts for a substantial proportion of deaths 
in adequately anticoagulated, contemporary patients 
with AF.6
Heart failure and AF are closely linked, and both 
conditions often occur concurrently, predisposing 
affected patients to poor outcomes.7,8 In addition, 
established therapies providing a survival benefit in 
most patients with heart failure, such as beta block-
ers, may be less effective in patients with heart failure 
and concomitant AF.9 Finally, AF- related treatment 
modalities that may improve outcomes in patients 
with heart failure, such as catheter ablation, are re-
stricted to a small group of selected patients in high- 
income countries.10
Thus, there is an unmet clinical need to identify 
potentially modifiable risk factors for heart failure 
hospitalization in patients with AF. Biomarkers of in-
flammation have been associated with incident ath-
erothrombotic events in multiple populations,11– 14 and 
an association with heart failure hospitalization has 
been shown in patients with prior myocardial infarc-
tion.15 However, there are no such studies in patients 
with AF, where underlying pathophysiologic patterns 
are mostly unrelated to ischemia and atherosclerosis. 
More data are therefore needed to assess whether 
biomarkers of inflammation are associated with heart 
failure hospitalization and other adverse outcomes in 
patients with AF.
METHODS
Data used to conduct this research may be made 
available for other researchers upon reasonable re-
quest, if the request is in line with the informed con-
sent signed by all patients. For all analyses, we used 
a combined data set of patients with documented AF 
enrolled in 2 prospective, multicenter cohort studies 
conducted in Switzerland. Between January 2010 
and August 2017, a total of 1553 and 2415 patients 
were enrolled in the BEAT- AF (Basel Atrial Fibrillation) 
and Swiss- AF (Swiss Atrial Fibrillation) studies, re-
spectively.16,17 Patients with AF due to reversible, 
secondary causes (eg, perioperative AF or AF due 
to severe electrolyte abnormalities) were excluded. 
Patients with any acute illness or who were hospital-
ized for any reason could be enrolled only at least 
4  weeks after the acute episode or hospital dis-
charge. Baseline visits were done in person in both 
cohorts. During this visit, an ECG was obtained in all 
patients. Cardiac rhythm at baseline was adjudicated 
based on these ECGs. Follow- up visits occurred at 
12- month intervals and were done either by mail and 
telephone (BEAT- AF), or in person (Swiss- AF). Co- 
enrollment in both cohorts was prohibited. A central 
study team located in Basel, Switzerland, coordi-
nated the conduct of both studies. Case report forms 
to collect information on clinical characteristics, co-
morbidities and medications, and general methodol-
ogy were very similar in the 2 cohorts.
In this study, we included all patients for whom at 
least 1 baseline measurement of either hs- CRP (high- 
sensitivity C- reactive protein) or interleukin- 6 (IL- 6) was 
available. We excluded 177 patients for whom infor-
mation on both biomarkers, prespecified covariates 
needed for the multivariable analyses, or follow- up was 
missing. After accounting for accidental co- enrollment 
of 7 patients in both cohorts, the final sample for this 
study comprised 3784 (95.4%) patients. Approval 
by the local research ethics boards at all participat-
ing sites was obtained before study initiation, and all 
study participants provided written informed consent. 
Swiss- AF is registered on Clini calTr ials.gov (identifier 
NCT02105844).
Biomarkers of Inflammation
At baseline, an EDTA plasma sample was obtained 
from each patient enrolled in either of the 2 cohort 
studies. Samples were immediately processed, ali-
quoted, and stored at −80°C. Commercially avail-
able assays (cobas c 311 and cobas Elecsys®, Roche 
CLINICAL PERSPECTIVE
What Is New?
• In a large, contemporary cohort of patients with 
atrial fibrillation, biomarkers of inflammation 
(hs- CRP [high- sensitivity C- reactive protein], in-
terleukin- 6) were strongly associated with hos-
pitalization for heart failure and other adverse 
outcomes during a median follow- up duration 
of 4.0 years.
• Large absolute risk differences for a first hospi-
talization for heart failure were observed across 
different categories of inflammation (eg, both 
hs- CRP and interleukin- 6 above the 75th per-
centile versus both biomarkers up to or below 
the 50th percentile, incidence 7.31 versus 1.34 
per 100 person- years) and a strong relationship 
persisted after multivariable adjustment (ad-
justed hazard ratio, 2.43; 95% CI, 1.80– 3.30).
What Are the Clinical Implications?
• Our study suggests that inflammation is an 
important predictor of hospitalization for heart 
failure and other adverse outcomes in patients 
with atrial fibrillation.
• Whether treatments targeted at inflammatory 
pathways can improve outcomes in patients 
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Diagnostics, Mannheim, Germany) were used to 
measure plasma levels of hs- CRP and IL- 6. All analy-
ses were centrally performed by Roche Diagnostics 
(Rotkreuz, Switzerland). A total of 6 and 3 patients had 
plasma levels below the detection limit for hs- CRP and 
IL- 6, respectively. The values for these patients were 
set to 0.01 mg/L for hs- CRP (lowest value observed in 
the remaining patients 0.02 mg/L) and 0.05 pg/mL for 
IL- 6 (lowest value observed in the remaining patients 
0.06 pg/mL).
Outcomes
All outcomes had standardized definitions and were 
independently adjudicated by at least 2 reviewers. The 
prespecified primary outcome for this analysis was 
time to first hospitalization for heart failure, defined as 
any unplanned hospitalization for signs and symptoms 
of heart failure associated with at least 1 overnight 
stay. Prespecified secondary outcomes were all- cause 
mortality, cardiovascular death, a composite end point 
of ischemic stroke, myocardial infarction or cardiovas-
cular death, and a composite end point of ischemic 
stroke or systemic embolism. The study definitions for 
each of these outcomes are provided in Table S1 and 
were identical in both cohorts.
Statistical Analysis
Continuous variables were visually inspected to deter-
mine the normality of distribution and were presented 
as mean± SD or median (interquartile range), as ap-
propriate. Plasma levels of both hs- CRP and IL- 6 were 
used to calculate a simple, prespecified inflammation 
score ranging from 0 to 4 (1 point for each biomarker 
between the 50th and 75th percentile, 2 points for 
each biomarker above the 75th percentile). The linear 
correlation between hs- CRP and IL- 6 was quantified 
using the Pearson correlation coefficient. Because 
biomarker distributions were strongly skewed, we 
log- transformed plasma levels of hs- CRP and IL- 6. 
Incidence rates for all outcomes were presented as 
number of events per 100 person- years.
For the primary analysis, multivariable Cox 
proportional- hazards models were built to quantify the 
individual associations of hs- CRP, IL- 6, and the inflam-
mation score with the outcomes of interest. Separate 
Cox models were built for the 2 biomarkers. We se-
lected model covariates a priori on the basis of clin-
ical considerations. Covariates included were age, 
sex, history of heart failure, hypertension, diabetes 
mellitus, prior stroke or transient ischemic attack, his-
tory of coronary artery disease, estimated glomerular 
filtration rate, body mass index, smoking status, use 
of oral anticoagulation, and study cohort (BEAT- AF or 
Swiss- AF). Patients who died during the time of fol-
low- up were censored. Results were presented as 
adjusted hazard ratios (HR) with 95% CIs per increase 
in 1 SD of log- transformed plasma levels of hs- CRP 
or IL- 6, and per 1- point increase of the inflammation 
score. Post hoc sensitivity analyses adding baseline 
statin use and cardiac rhythm at baseline to the models 
were performed to further investigate the associations 
between the inflammation score and adverse outcome 
events. We performed competing risk analyses using 
the method reported by Fine and Gray,18 accounting 
for the competing risks of death (first hospitalization for 
heart failure; composite of ischemic stroke or systemic 
embolism) and noncardiovascular death (cardiovas-
cular death; composite of ischemic stroke, myocar-
dial infarction or cardiovascular death), respectively. 
Unadjusted Kaplan- Meier curves were used to visual-
ize cumulative incidence rates for the primary outcome 
first hospitalization for heart failure and the secondary 
outcomes across inflammation score categories, cen-
soring patients who died during the time of follow- up. 
The log- rank test was used to assess between- group 
differences. Cumulative incidence function plots ac-
counting for competing risks were used for an alterna-
tive visualization of the incidences of the primary and 
secondary outcomes, and Gray’s test of equality was 
used to assess between- group differences.
For the primary outcome hospitalization for heart 
failure, we evaluated the possibility of nonlinear as-
sociations by entering a quadratic term for either log- 
transformed hs- CRP or log- transformed IL- 6 in the 
respective multivariable models. Subgroup analyses 
for the primary outcome according to sex, history 
of heart failure, AF type, history of coronary artery 
disease, and history of stroke or transient ischemic 
attack were specified a priori. Tests for interaction 
were performed in the nonstratified multivariable 
models using multiplicative interaction terms. A 2- 
sided P<0.05 was considered statistically significant. 




Baseline characteristics of the 3784 patients are 
shown in Table  1. The median (interquartile range) 
age was 72 (66– 78) years and 27.9% of patients were 
female. The proportion of patients with permanent AF 
was 23.0%. A total of 51.8% of patients were in sinus 
rhythm and 43.6% were in AF or atrial flutter at base-
line, respectively. A total of 23.8% had a history of 
heart failure and 26.6% had coronary artery disease. 
A total of 84.2% of patients received oral anticoagu-
lation at baseline, and 43.9% received a statin. A mi-
nority (7.9%) reported active tobacco use, and 48.0% 
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range) plasma levels of hs- CRP and IL- 6 at baseline 
were 1.64 (0.81– 3.69) mg/L and 3.42 (2.14– 5.60) pg/
mL, respectively. The Pearson correlation coefficient 
between log- transformed plasma levels of hs- CRP 
and IL- 6 was 0.57 (P<0.001).
Outcomes
During a median (interquartile range) follow- up of 4.0 
(2.9– 5.1) years, at least 1 hospitalization for heart 
failure occurred in 447 (11.8%) of patients, correspond-
ing to an incidence rate of 3.04 per 100 person- years 
(Table 2). After multivariable adjustment, both biomark-
ers were significantly associated with heart failure hos-
pitalization (per increase in 1 SD, adjusted HR, 1.22; 
95% CI, 1.11– 1.34; P<0.001 for log- transformed hs- 
CRP; adjusted HR, 1.48; 95% CI, 1.35– 1.62; P<0.001 
for log- transformed IL- 6). Although there was no evi-
dence for a nonlinear association for hs- CRP (P=0.999 
for quadratic log- transformed hs- CRP), there was evi-
dence of a nonlinear relationship for IL- 6 (β=−0.086, 
SE, 0.031, P=0.006 for quadratic log- transformed IL- 6), 
suggesting less steep increases in risk at higher IL- 6 
concentrations.
The incidence of heart failure hospitalization in-
creased across inflammation score categories, from 
1.34 (inflammation score 0) to 7.31 (score 4) per 100 
person- years (P<0.001; Figure). The inflammation score 
remained strongly associated with the risk of heart fail-
ure hospitalization after multivariable adjustment (high-
est score [score of 4] versus reference category [score 
of 0], adjusted HR, 2.43; 95% CI, 1.80– 3.30; P value 
for trend<0.001) (Table 3).
As shown in Table 2, both hs- CRP and IL- 6 were 
significantly associated with all- cause mortality, car-
diovascular death and the composite of ischemic 
stroke, myocardial infarction, or cardiovascular death 
after multivariable adjustment (all P<0.001). The as-
sociation of hs- CRP and IL- 6 with the composite end 
point of ischemic stroke or systemic embolism was 
weak. Consistent results were observed with the in-
flammation score (Table 3). Kaplan- Meier curves for 
the secondary outcomes stratified by inflammation 
score categories are shown in Figures  S1 through 
S4, and cumulative incidence function plots account-
ing for competing risks are shown in Figures  S5 
through S8.
For all outcomes, post hoc sensitivity analyses 
that additionally adjusted for baseline statin use and 
cardiac rhythm at baseline yielded consistent results 
(Table S2). Analyses that accounted for the competing 
risks of death and noncardiovascular death, respec-
tively, showed consistent results for the primary and 
secondary outcomes (Table S2).
Subgroup Analyses
The associations of hs- CRP and IL- 6 with the primary 
outcome across several subsets of patients are shown 
in Table  4. There were stronger relative associations 
with heart failure hospitalization in patients without 
a history of heart failure or coronary artery disease 
for both hs- CRP and IL- 6 (each P value for interac-
tion<0.05). There was no significant interaction with 
either biomarker according to sex, AF type, or history 
of stroke or transient ischemic attack.
Table 1. Baseline Characteristics
Baseline Variable n=3784
Age, y, median (IQR) 72.4 (66.2– 78.2)
Female sex, % 1054 (27.9)
Permanent atrial fibrillation, % 869 (23.0)
Cardiac rhythm at baseline
Sinus rhythm, % 1960 (51.8)
Atrial fibrillation or flutter, % 1649 (43.6)
Other, %* 175 (4.6)
CHA2DS2- VASc score, mean (SD)
† 3.2 (1.7)
Heart failure, % 899 (23.8)
Arterial hypertension, % 2603 (68.8)
Diabetes mellitus, % 597 (15.8)
Prior stroke or transient ischemic attack, % 646 (17.1)
Peripheral artery disease, % 277 (7.3)
Coronary artery disease, % 1008 (26.6)
Prior myocardial infarction, % 557 (14.7)
Estimated glomerular filtration rate, mL/min per 
1.73 m2 (Modification of Diet in Renal Disease), 
mean (SD)
65.7 (20.2)
Body mass index, kg/m2, median (IQR) 26.7 (24.2– 29.9)
Oral anticoagulation, % 3186 (84.2)
Direct oral anticoagulant, % 1336 (35.3)
Vitamin K antagonist, % 1850 (48.9)
Statin use, % 1660 (43.9)
Tobacco use
Never, % 1668 (44.1)
Past, % 1818 (48.0)
Active, % 298 (7.9)
Plasma levels of biomarkers
hs- CRP mg/L, median (IQR)‡ 1.64 (0.81– 3.69)
IL- 6, pg/mL, median (IQR)§ 3.42 (2.14– 5.60)
CHA2DS2- VASc indicates congestive heart failure, hypertension, age ≥ 
75 years, diabetes mellitus, stroke or transient ischemic attack, vascular 
disease, age 65 to 74 years, sex category; hs- CRP, high- sensitivity C- 
reactive protein; IL- 6, interleukin- 6; and IQR, interquartile range.
*Includes n=26 for whom baseline rhythm was not available.
†The CHA2DS2- VASc score ranges from 0 to 9 (1 point for each history of 
heart failure, hypertension, age 65 to 74 years, diabetes mellitus, vascular 
disease, and female sex; 2 points for each age >75 years and prior stroke or 
transient ischemic attack).
‡hs- CRP available for 3767 (99.6%) patients, range (min- max) 0.01 to 
198.04 mg/L.
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DISCUSSION
In this large, contemporary cohort of patients with 
AF, hs- CRP, and IL- 6 were strongly and consist-
ently associated with the risk of heart failure hos-
pitalization and other adverse clinical outcomes. 
These results persisted after extensive adjustment 
for other risk factors and comorbidities. Using a sim-
ple inflammation score, we found that patients with 
higher levels of both inflammatory biomarkers had a 
more than 5- fold higher absolute risk of heart failure 
hospitalization compared with those with lower levels 
of both biomarkers.
There has been an ongoing controversy around 
the inflammatory hypothesis in cardiovascular dis-
ease. Longitudinal studies in apparently healthy 
individuals have previously shown an association 
between elevated biomarkers of inflammation and 
future cardiovascular events.13,14 It is possible that in-
flammation may be a marker of underlying subclinical 
disease and established clinical risk factors, such as 
hypertension, diabetes mellitus, or obesity. Indeed, 
Table 2. Associations of Biomarkers of Inflammation With Adverse Outcome Events
Outcome Events
Rate Per 100 
Person- Years Marker
Univariable HR 
(95% CI) P Value
Adjusted HR 
(95% CI) P Value
Hospitalization for heart failure 447 3.04 hs- CRP 1.46 (1.33– 1.60) <0.001 1.22 (1.11– 1.34) <0.001
IL- 6 1.80 (1.67– 1.93) <0.001 1.48 (1.35– 1.62) <0.001
All- cause mortality 432 2.80 hs- CRP 1.62 (1.48– 1.78) <0.001 1.40 (1.27– 1.54) <0.001
IL- 6 1.97 (1.84– 2.11) <0.001 1.67 (1.53– 1.81) <0.001
Cardiovascular death 264 1.71 hs- CRP 1.54 (1.37– 1.73) <0.001 1.31 (1.16– 1.49) <0.001
IL- 6 1.97 (1.81– 2.15) <0.001 1.65 (1.49– 1.84) <0.001
Ischemic stroke, myocardial infarction 
or cardiovascular death
440 2.93 hs- CRP 1.42 (1.29– 1.55) <0.001 1.27 (1.15– 1.39) <0.001
IL- 6 1.71 (1.59– 1.85) <0.001 1.46 (1.34– 1.60) <0.001
Ischemic stroke or systemic embolism 121 0.80 hs- CRP 1.22 (1.03– 1.46) 0.026 1.21 (1.01– 1.45) 0.04
IL- 6 1.33 (1.13– 1.57) 0.001 1.19 (0.99– 1.44) 0.07
Because of positively skewed distribution of plasma levels of both hs- CRP and IL- 6, a logarithmic transformation was performed. Hazard ratios and 95% CIs 
are shown as per increase in 1SD of log- transformed concentrations of hs- CRP and IL- 6, respectively. Multivariable analyses were adjusted for age, sex, history 
of heart failure, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, history of coronary artery disease, estimated glomerular filtration rate 
as per Modification of Diet in Renal Disease formula, body mass index, smoking status, anticoagulation use, and study cohort (BEAT- AF [Basel Atrial Fibrillation] 
or Swiss- AF [Swiss Atrial Fibrillation]). Observations in model: 3767 (99.6% complete cases) for hs- CRP and 3667 (96.9% complete cases) for IL- 6. For patients 
excluded from the analyses, plasma levels of the respective biomarkers were missing. HR indicates hazard ratio; hs- CRP, high- sensitivity C- reactive protein; 
and IL- 6, interleukin- 6.
Figure. Cumulative incidence of heart failure hospitalization across inflammation score 
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even the most rigorously conducted epidemiological 
studies, including this one, are ultimately unable to 
prove a causal relationship between inflammation 
and outcomes. However, encouraging evidence from 
different populations is emerging and shows that in-
flammation may play a causal role. Three large ran-
domized clinical trials in patients with ischemic heart 
disease and/or a history of myocardial infarction con-
sistently demonstrated that anti- inflammatory drugs 
counteracting interleukin- 1β- mediated inflammation 
reduce the risk of ischemic events.19– 21 Of note, a 
post hoc analysis from 1 of these trials showed a 
dose- dependent reduction in heart failure hospital-
ization related to ischemic heart disease in patients 
randomized to canakinumab.15
As previous studies have focused on patients 
with atherosclerosis, it is unclear whether these find-
ings can be extrapolated to patients with AF, a het-
erogeneous population in whom the mechanisms for 
heart failure occurrence are mostly independent of 
overt ischemic heart disease. For instance, the great 
majority of patients in our cohort did not have coronary 
artery disease. Our results suggest that even in this 
patient population, inflammation may play a role in the 
occurrence of adverse outcomes, such as heart fail-
ure hospitalization or death. Subgroup analyses in our 
study suggested stronger associations of hs- CRP and 
IL- 6 with heart failure hospitalization in individuals with-
out a history of heart failure or coronary artery disease. 
The clinical significance of these findings is currently 
uncertain, but they support the hypothesis that inflam-
matory processes do play a role in patients without es-
tablished heart failure or coronary artery disease.
Even in a broader context, inflammation seems 
to play an important role in AF. Animal studies have 
highlighted the significance of NLRP3 inflammasome 
activation, by regulating cytokine- dependent path-
ways involved in the pathogenesis of AF and atrial 
remodeling.22 Further, elevated biomarkers indicat-
ing systemic inflammation have been linked to atrial 
remodeling,23 incident AF24 as well as arrhythmia 
burden in patients with established AF.25 Previous 
Table 3. Association of the Inflammation Score With Adverse Outcome Events
Outcome Inflammation Score Patients Events
Rate Per 100 
Person- Years
Adjusted HR (95% 
CI)
P Value for 
Trend
Hospitalization for heart 
failure
0 1280 75 1.34 Reference category
1 779 75 2.40 1.32 (0.96– 1.82) <0.001
2 616 76 3.22 1.45 (1.04– 2.00)
3 454 79 4.80 2.04 (1.48– 2.83)
4 521 120 7.31 2.43 (1.80– 3.30)
All- cause mortality 0 1280 43 0.75 Reference category
1 779 73 2.24 2.20 (1.50– 3.21) <0.001
2 616 82 3.33 2.85 (1.95– 4.15)
3 454 84 4.74 3.85 (2.64– 5.60)
4 521 137 7.51 4.96 (3.47– 7.09)
Cardiovascular death 0 1280 28 0.49 Reference category
1 779 51 1.57 2.36 (1.49– 3.76) <0.001
2 616 43 1.75 2.24 (1.38– 3.63)
3 454 53 2.99 3.61 (2.26– 5.77)
4 521 81 4.44 4.26 (2.72– 6.65)
Ischemic stroke, 
myocardial infarction or 
cardiovascular death
0 1280 74 1.31 Reference category
1 779 92 2.91 1.80 (1.32– 2.45) <0.001
2 616 68 2.84 1.55 (1.11– 2.17)
3 454 85 5.01 2.65 (1.92– 3.65)
4 521 112 6.42 2.86 (2.10– 3.90)
Ischemic stroke or 
systemic embolism
0 1280 34 0.60 Reference category
1 779 27 0.84 1.23 (0.74– 2.06) 0.03
2 616 14 0.58 0.81 (0.43– 1.53)
3 454 22 1.28 1.84 (1.05– 3.20)
4 521 23 1.29 1.76 (1.00– 3.07)
Multivariable analyses were adjusted for age, sex, history of heart failure, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, history 
of coronary artery disease, estimated glomerular filtration rate as per Modification of Diet in Renal Disease formula, body mass index, smoking status, 
anticoagulation use, and study cohort (BEAT- AF [Basel Atrial Fibrillation] or Swiss- AF [Swiss Atrial Fibrillation]). Observations in model: 3650 (96.5% complete 
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studies in patients with AF have shown that el-
evated levels of CRP or IL- 6 are associated with 
mortality.26– 29 Our study adds to these findings and 
suggests that inflammation is a strong predictor of 
adverse outcomes in patients with AF. Although our 
results should not prompt physicians to measure bio-
markers of inflammation or use our score as part of 
routine clinical care, we do think that they provide 
support for the initiation of clinical trials investigat-
ing the efficacy and safety of anti- inflammatory treat-
ments in this population. Whether or not biomarkers 
of inflammation should be repeatedly measured over 
time should be addressed in future studies.
Our simple inflammation score effectively strat-
ified heart failure risk among patients with AF in-
cluded in this study, suggesting an additive effect 
of the 2 evaluated biomarkers. There was a large 
absolute risk difference of about 6 heart failure hos-
pitalizations per 100 person- years between patients 
in the highest versus the lowest inflammation score 
category. Thus, although the risk of ischemic stroke 
or systemic embolism was low in this population with 
a high proportion of anticoagulation use, there is a 
significant number of patients with AF at high risk of 
other outcomes, and 2 readily available inflammatory 
biomarkers can efficiently risk stratify these patients. 
Randomized clinical trials are warranted to determine 
whether anti- inflammatory treatments can reduce 
the risk of heart failure hospitalization and other out-
comes in this patient population.
Strengths and Limitations
Key strengths of our study are the prospective design, 
the large sample size with a large number of outcome 
events, the high proportion of patients with complete 
data and the availability of 2 biomarkers of inflamma-
tion. The magnitude of increased risk of adverse out-
comes associated with high concentrations of hs- CRP 
and IL- 6, especially for heart failure hospitalization 
Table 4. Subgroup Analyses for the End Point Hospitalization for Heart Failure
Subgroup Group n/N
Rate Per 100 
Person- Years
Adjusted HR (95% 
CI)
P Value for 
Interaction
hs- CRP
All 3784/3784 3.04 1.22 (1.11– 1.34)
Sex Male 2730/3784 3.00 1.22 (1.09– 1.36) 0.95
Female 1054/3784 3.14 1.22 (1.00– 1.48)
History of heart failure Yes 899/3784 7.57 1.09 (0.95– 1.24) 0.04
No 2885/3784 1.92 1.34 (1.17– 1.53)
Type of atrial fibrillation Permanent 869/3784 5.49 1.28 (1.08– 1.52) 0.81
Nonpermanent 2915/3784 2.41 1.18 (1.05– 1.33)
History of coronary artery 
disease
Yes 1008/3784 5.66 1.04 (0.90– 1.20) 0.001
No 2776/3784 2.25 1.38 (1.21– 1.57)
History of stroke or transient 
ischemic attack
Yes 646/3784 4.11 1.13 (0.92– 1.40) 0.69
No 3138/3784 2.84 1.24 (1.11– 1.39)
IL- 6
All 3784/3784 3.04 1.48 (1.35– 1.62)
Sex Male 2730/3784 3.00 1.47 (1.32– 1.63) 0.94
Female 1054/3784 3.14 1.54 (1.27– 1.87)
History of heart failure Yes 899/3784 7.57 1.35 (1.18– 1.54) 0.04
No 2885/3784 1.92 1.59 (1.40– 1.80)
Type of atrial fibrillation Permanent 869/3784 5.49 1.70 (1.44– 2.00) 0.13
Nonpermanent 2915/3784 2.41 1.39 (1.24– 1.56)
History of coronary artery 
disease
Yes 1008/3784 5.66 1.26 (1.09– 1.46) 0.001
No 2776/3784 2.25 1.63 (1.44– 1.84)
History of stroke or transient 
ischemic attack
Yes 646/3784 4.11 1.35 (1.08– 1.69) 0.46
No 3138/3784 2.84 1.50 (1.36– 1.66)
Results are shown as adjusted HR per increase in 1 SD of log- transformed biomarker levels. Multivariable analyses were adjusted for age, sex, history of 
heart failure, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, history of coronary artery disease, estimated glomerular filtration rate as 
per Modification of Diet in Renal Disease formula, body mass index, smoking status, anticoagulation use, and study cohort (BEAT- AF [Basel Atrial Fibrillation] or 
Swiss- AF [Swiss Atrial Fibrillation]), excluding the covariate of interest for each subgroup. Observations in model: 3767 (99.6% complete cases) for hs- CRP and 
3667 (96.9% complete cases) for IL- 6. For patients excluded from the analyses, plasma levels of the respective biomarkers were missing. HR indicates hazard 
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and death, is striking. However, the associations do 
not prove causality, and our results may be subject to 
residual confounding, as discussed previously. In this 
cohort, women represented only about 28% of partici-
pants, which may limit the generalizability of our find-
ings to women with AF. However, subgroup analyses 
for the primary outcome hospitalization for heart fail-
ure did suggest consistent results according to sex. 
Because biomarkers of inflammation were measured 
only at the time of enrollment, we were unable to as-
sess the significance of changes in biomarker levels 
over time.
CONCLUSIONS
In this large, contemporary cohort of patients with 
AF, we found that biomarkers of inflammation were 
strongly associated with heart failure hospitalization 
and other adverse outcomes. Large absolute risk 
differences were observed across different levels of 
inflammation. Whether treatments targeted at inflam-
matory pathways can improve outcomes in patients 
with AF needs to be evaluated in randomized clinical 
trials.
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Table S1. Outcome definitions. 
Hospitalization for 
heart failure 
Hospitalization for acute heart failure is defined as: any hospitalization for acute heart failure that is 
associated with at least one overnight stay. If it’s not clear whether the reason for a patient’s 
hospitalization is acute heart failure or not, this event/incidence should in doubt be classified as acute 
heart failure. The following references mentioned under clinical examination, or in the progress entry 
could be used as an indication for heart failure: leg swelling/leg edema, distension of the neck veins, 
positive hepato-jugular reflux, rales and 3rd heart sound 
Mortality 
Deaths will be classified as either cardiovascular or non-cardiovascular. All deaths will be assumed to be 
cardiovascular in nature unless a non-cardiovascular cause can be clearly provided. Cardiovascular death: 
includes cardiac deaths (e.g. cardiogenic shock, arrhythmia/sudden death, cardiac rupture) and other 
vascular deaths (e.g., stroke, pulmonary embolism, ruptured aortic aneurysm or dissection). All 
hemorrhagic deaths will be classified as cardiovascular deaths. Non-cardiovascular death: includes all 
deaths due to a clearly documented non-cardiac and non-vascular cause, such as respiratory failure 










Defined as a rapid onset of focal neurological dysfunction with clinical, imaging or pathological evidence 
of focal infarction of the brain, retina (excluding anterior ischaemic optic neuropathy [AION]), or spinal 
cord explaining the dysfunction. Clinical evidence of infarction is based on symptoms persisting ≥24 
hours or until death, and exclusion of other aetiologies (such as brain infection, trauma, tumour, seizure, 
severe metabolic disease, or degenerative neurological disease). Transient neurological symptoms 
associated with cerebral infarction on imaging should be classified as ischaemic stroke, not TIA. 
Systemic embolism 
A systemic arterial embolism will be considered to have occurred where there is clear evidence of abrupt 
occlusion of a systemic artery consistent with an embolic event. Pulmonary embolism or deep vein 
thrombosis should not be reported. 
Myocardial infarction 
Myocardial infarction is defined according to the universal definition of MI as rise and/or fall of cardiac 
troponin with at least one value above the 99th percentile of the upper reference limit in a clinical setting 
consistent with myocardial ischemia, and with at least one of the following: 
- symptoms of ischemia 
- new ST elevation at the J point in two contiguous leads >0.1 mV except for V2-V3. For leads V2-V3 the 
following cut points apply: ≥0.2 mV in men ≥40 years, ≥0.25 mV in men <40 years and ≥0.15 mV in 








- new horizontal or down-sloping ST depression ≥0.05 mV in two contiguous leads and/or T inversion 
≥0.1 mV in two contiguous leads with prominent R wave or R/S ratio >1 
- new left bundle brunch block on ECG 
- development of pathological Q waves on ECG 
- imaging evidence of new loss of viable myocardium or new regional wall motion 































for heart failure 
0 Reference category Reference category Reference category 






2 1.38 (0.99-1.91) 1.31 (0.94-1.83) 1.45 (1.04-2.00) 
3 1.95 (1.41-2.70) 1.78 (1.28-2.47) 2.04 (1.48-2.83) 
4 2.29 (1.68-3.11) 2.08 (1.51-2.85) 2.43 (1.80-3.30) 
All-cause  
mortality 
0 Reference category 
 
Reference category 




2 2.76 (1.89-4.02) 2.85 (1.95-4.15) 
3 3.74 (2.57-5.45) 3.85 (2.64-5.60) 
4 4.79 (3.34-6.87) 4.96 (3.47-7.09) 
















2 2.16 (1.33-3.51) 2.10 (1.26-3.50) 2.24 (1.38-3.63) 
3 3.49 (2.18-5.56)  3.40 (2.09-5.52) 3.61 (2.26-5.77) 






0 Reference category Reference category Reference category 






2 1.50 (1.07-2.11) 1.46 (1.03-2.06)  1.55 (1.11-2.17) 
3 2.58 (1.87-3.56) 2.49 (1.79-3.45) 2.65 (1.92-3.65) 




0 Reference category Reference category Reference category 






2 0.77 (0.41-1.46) 0.75 (0.38-1.45) 0.81 (0.43-1.53) 
3 1.77 (1.01-3.09) 1.59 (0.89-2.85) 1.84 (1.05-3.20) 
4 1.60 (0.90-2.83) 1.45 (0.81-2.63) 1.76 (1.00-3.07) 
 
All analyses were adjusted for age, sex, history of heart failure, hypertension, diabetes, prior stroke or transient ischemic attack, 
history of coronary artery disease, estimated glomerular filtration rate (eGFR) as per MDRD formula, body mass index, smoking 








and cardiac rhythm at baseline. The competing risk analyses additionally accounted for death (first hospitalization for heart failure; 
composite of ischemic stroke or systemic embolism) and non-cardiovascular death (cardiovascular death; composite of ischemic 
stroke, myocardial infarction or cardiovascular death), respectively. Observations in model for the sensitivity analyses: 3,624 (95.8% 
complete cases due to missing information on plasma levels of hs-CRP or IL-6, or missing cardiac rhythm at baseline). Observations 































Figure S3. Cumulative incidence of ischemic stroke, myocardial infarction or cardiovascular death across inflammation score 





















Figure S5. Cumulative incidence function of heart failure hospitalization across inflammation score categories, accounting for 










Figure S6. Cumulative incidence function of cardiovascular death across inflammation score categories, accounting for the 










Figure S7. Cumulative incidence function of ischemic stroke, myocardial infarction or cardiovascular death across categories 










Figure S8. Cumulative incidence function of ischemic stroke or systemic embolism across categories of the inflammation score, 
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